Principal Financial Group Inc. Buys 14,795 Shares of Boston Scientific Corporation $BSX

Principal Financial Group Inc. raised its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 0.9% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,686,453 shares of the medical equipment provider’s stock after purchasing an additional 14,795 shares during the period. Principal Financial Group Inc. owned 0.11% of Boston Scientific worth $105,825,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also modified their holdings of the company. Chicago Partners Investment Group LLC boosted its holdings in shares of Boston Scientific by 82.6% in the 1st quarter. Chicago Partners Investment Group LLC now owns 13,396 shares of the medical equipment provider’s stock worth $869,000 after purchasing an additional 6,058 shares during the period. Triglav Investments D.O.O. raised its holdings in Boston Scientific by 34.1% during the 1st quarter. Triglav Investments D.O.O. now owns 29,500 shares of the medical equipment provider’s stock valued at $1,851,000 after buying an additional 7,500 shares during the period. LGT Fund Management Co Ltd. lifted its position in Boston Scientific by 61.7% in the first quarter. LGT Fund Management Co Ltd. now owns 95,955 shares of the medical equipment provider’s stock worth $6,021,000 after buying an additional 36,611 shares during the last quarter. Associated Banc Corp boosted its stake in Boston Scientific by 28.5% during the first quarter. Associated Banc Corp now owns 480,358 shares of the medical equipment provider’s stock worth $30,142,000 after buying an additional 106,526 shares during the period. Finally, ARQ Wealth Advisors LLC purchased a new position in Boston Scientific during the first quarter worth $408,000. 89.07% of the stock is owned by institutional investors.

Boston Scientific Trading Up 1.0%

Shares of BSX opened at $43.08 on Thursday. The firm has a market capitalization of $64.02 billion, a price-to-earnings ratio of 18.02, a PEG ratio of 0.82 and a beta of 0.58. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22. Boston Scientific Corporation has a 1-year low of $42.20 and a 1-year high of $109.50. The company has a 50-day moving average of $48.62 and a 200 day moving average of $66.39.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. The business had revenue of $5.20 billion for the quarter, compared to the consensus estimate of $5.19 billion. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The company’s revenue for the quarter was up 11.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.75 EPS. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, research analysts expect that Boston Scientific Corporation will post 3.36 EPS for the current year.

Boston Scientific declared that its Board of Directors has initiated a stock buyback program on Monday, May 18th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the medical equipment provider to repurchase up to 6.4% of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s board of directors believes its shares are undervalued.

Insider Buying and Selling

In other news, Director Cheryl Pegus bought 1,770 shares of the stock in a transaction on Wednesday, May 20th. The stock was acquired at an average cost of $56.49 per share, for a total transaction of $99,987.30. Following the acquisition, the director owned 1,770 shares of the company’s stock, valued at $99,987.30. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Edward J. Ludwig purchased 3,580 shares of the company’s stock in a transaction dated Wednesday, May 20th. The shares were purchased at an average cost of $56.68 per share, for a total transaction of $202,914.40. Following the transaction, the director directly owned 25,359 shares in the company, valued at approximately $1,437,348.12. This represents a 16.44% increase in their position. The SEC filing for this purchase provides additional information. Insiders have bought a total of 9,800 shares of company stock valued at $554,012 over the last quarter. 0.34% of the stock is owned by corporate insiders.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Analysts still see meaningful upside in Boston Scientific despite near-term concerns, with one note highlighting a bullish rating and a price target that remains well above the current share price. Boston Scientific (BSX) Faces WATCHMAN Slowdown But Analysts Still See Upside
• Neutral Sentiment: Boston Scientific was mentioned in a broader large-cap stock roundup, but the article did not add any new company-specific catalyst. 1 Large-Cap Stock with Exciting Potential and 2 We Turn Down
• Negative Sentiment: Management commentary pointed to a slowdown in WATCHMAN, and Needham lowered its price target to $57 from $77, signaling reduced optimism about near-term growth. Boston Scientific (BSX) Faces WATCHMAN Slowdown But Analysts Still See Upside
• Negative Sentiment: The company recently initiated voluntary Class II recalls of CRE and CRE Pro Wireguided endoscopy devices worldwide due to potential sterile packaging breaches, increasing quality and regulatory risk. Are Boston Scientific’s (BSX) Sterile-Packaging Recalls Reframing the Narrative on Quality and Regulatory Risk?
• Negative Sentiment: Recent coverage also noted that Boston Scientific stock fell in the latest session despite broader market gains, reinforcing investor concerns about momentum and execution. Boston Scientific (BSX) Stock Drops Despite Market Gains: Important Facts to Note

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the stock. Wall Street Zen downgraded shares of Boston Scientific from a “buy” rating to a “hold” rating in a research note on Saturday, March 28th. Wolfe Research cut shares of Boston Scientific from an “outperform” rating to a “peer perform” rating in a research note on Friday, May 29th. Leerink Partners cut their price target on shares of Boston Scientific from $87.00 to $74.00 and set an “outperform” rating on the stock in a report on Thursday, May 28th. Robert W. Baird set a $70.00 price objective on shares of Boston Scientific in a research report on Thursday, May 28th. Finally, Canaccord Genuity Group dropped their target price on Boston Scientific from $71.00 to $70.00 and set a “buy” rating for the company in a research report on Monday, June 1st. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $79.92.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.